Q2 2026 saw 11% revenue growth and 36% higher adjusted EBITDA, with gross margin expanding 260bps. Guidance for 2026 was raised, reflecting strong clinical and NGS performance, margin expansion, and robust cash flow. Debt maturity was extended and infrastructure investments advanced.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.